Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion

Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020. REUTERS/Arnd Wiegmann/File Photo Purchase Licensing Rights, opens new tab March 27 (Reuters) - Swiss pharma company Novartis (NOVN.S), opens new tabsaid on Friday it will acquire California-based biotech company Excellergy ...